Company intelligence / Profile preview

Oncoinvent AS

Ownership: Public · ONCIN
Development stage: Phase 2

Overview

Oncoinvent’s lead product candidate Radspherin® has completed Phase 1 safety and biodistribution studies with good patient recruitment. The company has amended both ongoing Phase 1 trials into Phase 2a to gather additional data. Early results show significant reduction in tumor cell growth and promising long-term survival rates for patients with peritoneal carcinomatosis of colorectal origin

Therapeutic areas: Oncology
Modalities: Radiopharmaceuticals (specifically alpha-emitting radioactive microspheres)
Industry: Biotech

Drug pipeline

2 assets

lead-212 labeled calcium carbonate microparticles

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Oncoinvent AS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncoinvent AS.

Explore the full profile